Furthermore, progression-free survival in lung cancer patients with ‘YDJC-high and CDC16-low’ showed higher HR value and improved p-value compared to lung cancer patients with YDJC-high (increase from 1.43 to 1.5 and decrease from 0.01 to 0.0016) (Figure 7D). This evidence concerns the gene CDC16 and lung cancer.